Development of Respiratory Syncytial Virus and Universal Influenza Virus Vaccines Conformationally Stabilized by Targeted Dityrosine Crosslinking

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Vice President, Research and Development, Calder Biosciences, Inc.
    Biography

      Dr. Yondola is Vice President, Research and Development at Calder Biosciences Inc. in Brooklyn, NY.  Dr. Yondola has extensive training in virology and vaccine development and his work is currently focused on designing and developing conformationally stabilized recombinant subunit vaccines immunogens for respiratory syncytial virus and influenza virus.  Calder utilizes a conformational stabilization technology based on targeted dityrosine crosslinks that are engineered into proteins/complexes in order to develop otherwise intractable vaccines.  He obtained his Ph.D. from Stony Brook University where his work focused on the biochemical and biophysical characterization of the adenovirus E4-ORF3 protein and his postdoctoral training was at the Mt. Sinai Medical Center focusing on influenza virus biology and universal influenza virus vaccine development.  Dr. Yondola, has been at Calder Biosciences since 2013, where he headed the universal influenza and respiratory syncytial virus vaccine programs, and now directs the company’s research & development.


    Abstract

    While viral fusion proteins are highly desirable for subunit vaccine generation, their inherent metastable nature complicates implementation and development.  We have harnessed the structural rigidity that dityrosine bonding imparts as a means of surmounting these difficulties.  Dityrosine bonds are naturally occurring and are formed through multiple reaction mechanisms including photo-activation, chemical, and enzymatic catalyzation.  While most in vitro reaction mechanisms are too harsh for the maintenance of protein conformation, we have modulated the enzymatic reaction in order to target crosslinks to specific regions of fully-folded protein immunogens in order to maintain potently neutralizing conformational epitopes or preserve conformational integrity in otherwise unstable molecules.    By focusing Ab responses toward desired epitopes, dityrosine-stabilized immunogens elicit focused and more potently neutralizing Ab responses, and thus improve their performance as vaccine immunogens.

    Learning Objectives:
    1. Describe the inherent stability issues for viral fusion proteins that make them difficult to use as subunit vaccines

    2. Describe the characteristics of dityrosine crosslinking in terms of bond length, length of reaction, bond characteristics, and when the bond is introduced

    3. Describe the attributes that dityrosine bonding imparts on the RSV F protein

    4. Describe the advantage of formulation of DT-preF on AdvaxSM

    5. Describe the characteristics of Headless HA that make it well suited as a dityrosine bond substrate.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources